Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52: 151939. https://doi.org/10.1016/j.semarthrit.2021.11.009.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Biosimilars in the EU: information guide for healthcare professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 14 Dec 2023.

US Food and Drug Administration. Questions and answers on biosimilar development and the BPCI act: GUIDANCE for industry. 2021. https://www.fda.gov/media/119258/download. Accessed 14 Dec 2023.

World Health Organization. Guidelines on evaluation of similar biological products. 2021. https://cdn.who.int/media/docs/default-source/biologicals/ecbs/who-sbps_22-april-2021.pdf?sfvrsn=f283c924_5. Accessed 14 Dec 2023.

Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov. 2003;2(9):693–4. https://doi.org/10.1038/nrd1182.

Article  CAS  PubMed  Google Scholar 

Coghlan J, He H, Schwendeman AS. Overview of Humira® biosimilars: current European landscape and future implications. J Pharm Sci. 2021;110(4):1572–82. https://doi.org/10.1016/j.xphs.2021.02.003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Everhov ÅH, Söderling J, Befrits G, et al. Increasing healthcare costs in inflammatory bowel disease 2007–2020 in Sweden. Aliment Pharmacol Ther. 2023;58(7):692–703. https://doi.org/10.1111/apt.17675.

Article  PubMed  Google Scholar 

European Medicines Agency. Summary of product characteristics: Humira. 2009. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf. Accessed 14 Dec 2023.

European Medicines Agency. Summary of product characteristics: Hyrimoz. 2018. https://www.ema.europa.eu/en/documents/product-information/hyrimoz-epar-product-information_en.pdf. Accessed 14 Dec 2023.

US Food and Drug Administration. HYRIMOZ (adalimumab-adaz) injection, for subcutaneous use. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761071s015lbl.pdf. Accessed 14 Dec 2023.

von Richter O, O’Reilly T, Guerrieri D, et al. GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar. Expert Opin Biol Ther. 2023;23:749–58. https://doi.org/10.1080/14712598.2022.2117546.

Article  CAS  Google Scholar 

Nabi H, Georgiadis S, Loft AG, et al. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Ann Rheum Dis. 2021;80(11):1400–9. https://doi.org/10.1136/annrheumdis-2021-219951.

Article  CAS  PubMed  Google Scholar 

Di Giuseppe D, Lindstrom U, Bower H, et al. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford). 2022;61(9):3596–605. https://doi.org/10.1093/rheumatology/keab933.

Article  CAS  PubMed  Google Scholar 

Puig L, Shams K, Furlan F, et al. Real-world effectiveness and safety of SDZ-ADL (adalimumab biosimilar) in patients with psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Biologics. 2022;2(4):213–25. https://doi.org/10.3390/biologics2040017.

Article  Google Scholar 

Blauvelt A, Lacour JP, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–31. https://doi.org/10.1111/bjd.16890.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Leonardi CL, Gaylis N, et al. Treatment with SDZ-ADL, an adalimumab biosimilar, in patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis: results of patient-reported outcome measures from two phase III studies (ADMYRA and ADACCESS). BioDrugs. 2021;35(2):229–38. https://doi.org/10.1007/s40259-021-00470-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wiland P, Jeka S, Dokoupilová E, et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study. BioDrugs. 2020;34(6):809–23. https://doi.org/10.1007/s40259-020-00447-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baraliakos X, Østergaard M, Poddubnyy D, et al. Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomized phase IIIb study [abstract]. Arthritis Rheumatol. 2022;74(suppl 9):L15.

Google Scholar 

von Richter O, Lemke L, Haliduola H, et al. Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar. Expert Opinion Biol Ther. 2019;19(10):1057–64. https://doi.org/10.1080/14712598.2019.1603959.

Article  CAS  Google Scholar 

von Richter O, Lemke L, Haliduola H, et al. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opinion Biol Ther. 2019;19(10):1075–83. https://doi.org/10.1080/14712598.2019.1571580.

Article  CAS  Google Scholar 

Baraliakos X, Østergaard M, Gensler LS, et al. Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS). Clin Drug Investig. 2020;40(3):269–78. https://doi.org/10.1007/s40261-020-00886-7.

Article  CAS  PubMed  Google Scholar 

Baraliakos X, Østergaard M, Poddubnyy D, et al. OP0059 Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomised phase IIIB study. Ann Rheum Dis. 2023;82(Suppl 1):38–40. https://doi.org/10.1136/annrheumdis-2023-eular.301.

Article  Google Scholar 

Novartis. Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation. 2023. https://www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation. Accessed 14 Dec 2023.

Novartis. Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation. 2023. https://www.novartis.com/news/media-releases/sandoz-receives-approval-european-commission-hyrimoz-adalimumab-high-concentration-formulation. Accessed 14 Dec 2023.

Bader LI, Solberg SM, Kaada SH, et al. Assays for infliximab drug levels and antibodies: a matter of scales and categories. Scand J Immunol. 2017;86(3):165–70. https://doi.org/10.1111/sji.12572.

Article  CAS  PubMed  Google Scholar 

Loft N, Egeberg A, Rasmussen MK, et al. Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676–83. https://doi.org/10.1001/jamadermatol.2021.0221.

Article  PubMed  Google Scholar 

Colaci M, Aprile ML, La Rosa A, Di Maggio A, Malatino L. AB0218 non-medical switch from adalimumab originator to the biosimilar GP2017 in patients affected by chronic arthritis. Ann Rheum Dis. 2021;80(Suppl 1):1135. https://doi.org/10.1136/annrheumdis-2021-eular.1563.

Article  Google Scholar 

Jyssum I, Gehin JE, Kristianslund E, et al. POS0252 Differences in serum drug levels and anti-drug antibodies in patients with inflammatory arthritis treatment with originator vs biosimilar adalimumab. Ann Rheum Dis. 2023;82(Suppl 1):POS0252. https://doi.org/10.1136/annrheumdis-2023-eular.1373.

Article  Google Scholar 

Lontai L, Gonczi L, Balogh F, et al. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study. Dig Liver Dis. 2022;54(12):1639–45. https://doi.org/10.1016/j.dld.2022.07.004.

Article  CAS  PubMed  Google Scholar 

Mocci G, Bodini G, Allegretta L, et al. Adalimumab biosimilar GP2017 versus adalimumab originator in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study. Biomedicines. 2022;10(8):1799. https://doi.org/10.3390/biomedicines10081799.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wasserbauer M, Hlava S, Drabek J, et al. Adalimumab biosimilars in the therapy of Crohn’s disease and ulcerative colitis: prospective multicentric clinical monitoring. PLoS ONE. 2022;17(8): e0271299. https://doi.org/10.1371/journal.pone.0271299.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gros B, Soto Escribano P, Marín Pedrosa S, Medina Medina R, Benítez JM, Iglesias-Flores E. P534 Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission. J Crohns Colitis. 2022;16(Suppl 1): i486. https://doi.org/10.1093/ecco-jcc/jjab232.661.

Article  Google Scholar 

Tursi A, Mocci G, Allegretta L, et al. Comparison of performances of adalimumab biosimilars SB5, ABP501, GP2017, and MSB11022 in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study. Inflamm Bowel Dis. 2023;29(3):376–83. https://doi.org/10.1093/ibd/izac092.

Article  PubMed  Google Scholar 

Tursi A, Mocci G, Cuomo A, et al. Replacement of adalimumab originator to adalimumab biosimilar for a non-medical reason in patients with inflammatory bowel disease: a real-life comparison of adalimumab biosimilars currently available in Italy. J Gastrointest Liver Dis. 2022;31(4):411–6. https://doi.org/10.15403/jgld-4608.

Article